Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 10/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13572504 | 0.90 | MAPT (0.39) | MAPTAPLNRRAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4277137 | 0.90 | MAPT (0.39) | MAPTAPLNRRAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4552948 | 0.84 | MAPT (0.42) | MAPTAPLNRRAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4277845 | 0.84 | MAPT (0.42) | MAPTAPLNRRAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13573331 | 0.82 | HSD17B2 (0.33) | SMN1; SMN2POLB | |
| SCHEMBL13572505 | 0.76 | ALOX12 (0.38) | MAPTAPLNRRAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13573330 | 0.73 | RIPK1 (0.39) | MAPTHPGDL3MBTL1POLB | |
| SCHEMBL4275512 | 0.73 | SMN1; SMN2 (0.35) | SMN1; SMN2L3MBTL1POLBLMNA | |
| SCHEMBL13572503 | 0.73 | SMN1; SMN2 (0.35) | SMN1; SMN2L3MBTL1POLBLMNA | |
| SCHEMBL16925413 | 0.68 | KCNA3 (0.44) | MAPTAPLNRRAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312335-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-12-17 | — | — | US | disclosed |
| WO-2007050510-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312335-A1 | Hiv Integrase Inhibitors | RECQL, TYMP, POLR2H | MAPT 2808/4885APLNR 4879/4885RAB9A 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.